Quince Therapeutics (QNCX) Projected to Post Earnings on Wednesday

Quince Therapeutics (NASDAQ:QNCX) is projected to post its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Quince Therapeutics to post earnings of ($1.5580) per share for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Quince Therapeutics Stock Up 0.8%

QNCX stock opened at $1.23 on Wednesday. The company has a market cap of $20.05 million, a PE ratio of -0.07 and a beta of 1.45. The business has a 50-day simple moving average of $1.16 and a 200 day simple moving average of $15.43. Quince Therapeutics has a 52 week low of $0.80 and a 52 week high of $45.50.

Institutional Trading of Quince Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new stake in Quince Therapeutics in the second quarter valued at approximately $37,000. Bridgeway Capital Management LLC boosted its holdings in Quince Therapeutics by 20.9% in the second quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock valued at $212,000 after acquiring an additional 22,200 shares during the last quarter. Hudson Bay Capital Management LP bought a new stake in Quince Therapeutics in the fourth quarter valued at approximately $213,000. Quadrature Capital Ltd bought a new stake in Quince Therapeutics in the fourth quarter valued at approximately $268,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in Quince Therapeutics in the fourth quarter valued at approximately $308,000. 30.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Wall Street Zen downgraded Quince Therapeutics to a “strong sell” rating in a research note on Saturday, April 18th. Maxim Group downgraded Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Lucid Cap Mkts downgraded Quince Therapeutics from a “strong-buy” rating to a “strong sell” rating in a research note on Friday, January 30th. downgraded Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 29th. Finally, Citigroup downgraded Quince Therapeutics from a “market outperform” rating to a “market perform” rating in a research note on Friday, January 30th. Five analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Quince Therapeutics currently has a consensus rating of “Reduce” and an average price target of $65.00.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.